双歧杆菌V9对便秘和腹泻患者的临床研究

目的研究益生菌双歧杆菌V9对便秘和腹泻患者的临床治疗效果,为该菌株的临床应用提供数据支持。方法以153例患有便秘或急慢性腹泻的患者为研究对象,对双歧杆菌V9菌粉进行为期3 w的临床试验验证,菌粉服用剂量为1.0×1010cfu/d。试验期间,每3天记录一次受试患者的排便频率和粪便形态,并在试验前和试验后采集粪便,测定受试患者体内主要肠道菌群的变化。结果试验结果证明,连续3 w服用双歧杆菌V9菌粉,对便秘、急性腹泻和慢性腹泻患者的治疗有效率分别为95.3%、95.4%和89.9%,与试验前相比,患者粪便中双歧杆菌数量显著增加(P<0.01),肠杆菌、肠球菌、拟杆菌和产气荚膜杆菌的数量也发生了不同程度的变化(P<0.01),接近健康人群肠道菌群结构。结论临床研究表明,双歧杆菌V9具有调节肠道菌群的作用,对便秘和急慢性腹泻患者治疗效果显著。

THE CLINICAL STUDY ON THE EFFECT OF BIFIDOBACTERIUM ANIMALS V9 IN PATIENTS WITH CONSTIPATION AND DIARRHEA

Objectives To observe the therapeutic effect of Bifidobacterium animalis V9 on patients with constipation and diarrhea.Method One hundred fifty-three patients with constipation,acute diarrhea and chronic diarrhea were given B.animalis V9 freeze-dried powder for 3 w and the dose was 1.0×1010cfu/d.The defecation frequencies and fecal properties of patients were recorded every three days and intestinal microflora was evaluated before and after experiment.Results The effective rates of B.animalis V9 on patients with constipation,acute diarrhea and chronic diarrhea were 95.3%,95.4% and 89.9% respectively after po B.animalis V9 freeze-dried powder for 3 w,The number of bifidobacteria in fecals increased(p<0.01) significantly compared with 3 w before,and colibacillus,enterococcus,bacteroid and clostridia also changed in different degree and closed to the healthy men.Conclusion B.animalis V9 can regulate the intestinal microflora and has communities,had remarkable cured effect on patients with constipation and diarrhea.